News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,355 Results
Type
Article (8019)
Company Profile (143)
Press Release (480193)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166766)
Career Advice (304)
Deals (25741)
Drug Delivery (7)
Drug Development (52878)
Employer Resources (14)
FDA (9763)
Job Trends (8572)
News (238229)
Policy (17901)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (500)
Accelerated approval (29)
ADA (18)
Adcomms (1)
Allergies (102)
Alliances (33164)
ALS (121)
Alzheimer's disease (1002)
Antibody-drug conjugate (ADC) (329)
Approvals (10480)
Artificial intelligence (370)
ASCO (161)
Autoimmune disease (241)
Automation (34)
Bankruptcy (263)
Belgium (4)
Best Places to Work (6957)
BIO (36)
Biologics (44)
BIOSECURE Act (1)
Biosimilars (123)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (24)
Bladder cancer (145)
Brain cancer (35)
Breast cancer (544)
Cancer (4033)
Cardiovascular disease (238)
Career advice (245)
Career pathing (1)
CAR-T (187)
CDC (2)
CDMO (30)
Celiac Disease (3)
Cell therapy (514)
Cervical cancer (36)
Clinical research (48469)
Collaboration (1362)
Commercialization (26)
Compensation (1614)
Complete response letters (36)
COVID-19 (773)
CRISPR (68)
C-suite (859)
Cystic fibrosis (89)
Data (6393)
Denatured (4)
Depression (108)
Dermatology (97)
Diabetes (382)
Diagnostics (4267)
Digital health (42)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (170)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (174)
Earnings (74022)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (237)
Events (88847)
Executive appointments (738)
Eye disease (3)
FDA (12686)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (999)
Gene editing (132)
Generative AI (13)
Gene therapy (352)
GLP-1 (312)
Government (953)
Grass and pollen (2)
Guidances (281)
Healthcare (9399)
Hematology (95)
HIV (56)
Huntington's disease (28)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (81)
Immunology and inflammation (113)
Immuno-oncology (71)
Indications (185)
Infectious disease (980)
Inflammatory bowel disease (141)
Inflation Reduction Act (4)
Influenza (89)
Intellectual property (271)
Interviews (41)
IPO (12401)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (89)
Layoffs (59)
Legal (5195)
Licensing (50)
Liver cancer (47)
Longevity (27)
Lung cancer (580)
Lung diease (9)
Lymphoma (269)
Machine learning (30)
Management (3)
Manufacturing (620)
Marketing (21)
MASH (122)
Medical affairs (2)
Medical device (8716)
Medtech (8906)
Mergers & acquisitions (14460)
Metabolic disorders (771)
mRNA (73)
Multiple sclerosis (117)
Multispecific (3)
NASH (4)
Netherlands (3)
Neurodegenerative disease (242)
Neuropsychiatric disorders (40)
Neuroscience (1953)
Neurotech (2)
NextGen: Class of 2026 (3150)
Non-profit (844)
Obesity (242)
Opinion (10)
Ovarian cancer (181)
Pain (194)
Pancreatic cancer (232)
Parkinson's disease (217)
Partnered (12)
Patents (525)
Patient advocacy (3)
Patient recruitment (549)
Patient selection (47)
Peanut (33)
People (41547)
Peptides (16)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15642)
Phase 2 (21659)
Phase 3 (14622)
Pipeline (8496)
Policy (18)
Postmarket research (1570)
Preclinical (6599)
Press Release (34)
Prostate cancer (209)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (626)
Real estate (3027)
Recruiting (6)
Regenerative medicine (13)
Regulatory (15200)
Reports (23)
Research institute (593)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (110)
Series A (177)
Series B (126)
Service/supplier (5)
Sickle cell disease (66)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2022)
Stem cells (2)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (56)
Tariffs (2)
Vaccines (353)
Venture capital (17)
Weight loss (77)
Wet AMD (3)
Women's health (100)
Date
Today (25)
Last 7 days (485)
Last 30 days (1737)
Last 365 days (19232)
2026 (15907)
2025 (19251)
2024 (22988)
2023 (26539)
2022 (34589)
2021 (37168)
2020 (33468)
2019 (23257)
2018 (17469)
2017 (18766)
2016 (17917)
2015 (24271)
2014 (21688)
2013 (18139)
2012 (20233)
2011 (20446)
2010 (20336)
Location
Africa (232)
Alabama (80)
Alaska (2)
Arizona (322)
Arkansas (12)
Asia (18073)
Australia (2124)
California (12975)
Canada (3374)
China (586)
Colorado (532)
Connecticut (453)
Delaware (230)
Europe (24849)
Florida (1949)
Georgia (411)
Hawaii (3)
Idaho (46)
Illinois (780)
India (62)
Indiana (335)
Iowa (19)
Japan (458)
Kansas (104)
Kentucky (33)
Louisiana (28)
Maine (27)
Maryland (1281)
Massachusetts (8475)
Michigan (322)
Minnesota (602)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (134)
New Hampshire (61)
New Jersey (2852)
New Mexico (12)
New York (3038)
North Carolina (1374)
North Dakota (4)
Northern California (6566)
Ohio (305)
Oklahoma (15)
Oregon (17)
Pennsylvania (2415)
Puerto Rico (24)
Rhode Island (31)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5419)
Tennessee (128)
Texas (2140)
United States (42022)
Utah (396)
Vermont (1)
Virginia (168)
Washington D.C. (39)
Washington State (997)
West Virginia (1)
Wisconsin (82)
Wyoming (1)
488,355 Results for "agendia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach
October 26, 2026
·
3 min read
Press Releases
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026
October 6, 2026
·
4 min read
Press Releases
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
April 30, 2026
·
3 min read
Press Releases
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
May 22, 2026
·
5 min read
Press Releases
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
May 4, 2026
·
4 min read
Press Releases
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
January 20, 2026
·
4 min read
Press Releases
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
November 26, 2025
·
5 min read
Press Releases
Agendia, Inc. Provides Review of Successful 2024
January 9, 2025
·
7 min read
Press Releases
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium
November 5, 2025
·
3 min read
Biotech Beach
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
February 1, 2024
·
4 min read
1 of 48,836
Next